After more than three decades in biotechnology and immuno-oncology, I’ve had the privilege of contributing to the discovery and development of several antibody therapeutics and innovative biologics programs. My career has taken me from academic research to leadership roles at companies such as Bristol-Myers Squibb, Medarex, Takeda/Maverick Therapeutics, and 4D Molecular Therapeutics, where I’ve worked alongside talented teams to advance new therapies for patients. I’m excited to continue advising companies and exploring opportunities to contribute at the board level. Here is my biography.

Klodjan Stafa is a visionary biomedical research leader with a proven track record of advancing innovation at the intersection of dermatology, neuroscience, and molecular biology. With over 15 years of experience spanning academia and industry, he leads high-impact R&D initiatives that drive product development and business growth on a global scale. Known for his ability to cultivate top-performing teams and foster strategic partnerships, Klodjan combines scientific depth with business acumen to deliver breakthrough solutions. His work has contributed to multi-million dollar product launches, influential publications, and patented technologies, positioning him as a trusted voice in translational science and a catalyst for meaningful change in biomedical research.

Raymond Chang is a seasoned Translational Imaging Scientist with over two decades of experience spanning pharmaceutical research, contract research organizations, and academic discovery. Renowned for his expertise in advanced imaging modalities such as PET, SPECT, and CT, Chang has contributed significantly to the development of preclinical disease models and innovative therapeutics. His career highlights include leading the enterprise implementation of multimodality bioinformatics systems, developing cutting-edge imaging tools, and managing GLP and Non-GLP studies that bridge preclinical and clinical research. A dedicated leader and collaborator, Chang excels in regulatory compliance, experimental design, and fostering partnerships, making him a pivotal figure in advancing personalized medicine and imaging science.